Cyclophosphamide-free mobilisation increases safety while preserving the efficacy of autologous haematopoietic stem cell transplantation in refractory Crohn's disease patients.

Antonio GiordanoMontserrat RoviraMarisol VenyRebeca BarasteguiPedro MarínCarmen MartínezFrancesc Fernández-AvilésMaría Suárez-LledóAriadna DomènechAnna SerrahimaMiquel LozanoJoan CidIngrid OrdásAgnés Fernández-ClotetBerta CaballolMarta GallegoAlejandro VaraMaria Carme MasamuntÀngel GinerIris TeubelMiriam EstellerAnna María CorralizaJulian PanésAzucena SalasElena Ricart

Published in: Journal of Crohn's & colitis (2024)

Cy-free mobilisation is safe and feasible in refractory CD patients undergoing AHSCT. Although relapse occurs in a significant proportion of patients, clinical and endoscopic responses are achieved upon CD-specific therapy reintroduction.

Keyphrases

stem cell transplantation
end stage renal disease
patients undergoing
newly diagnosed
ejection fraction
high dose
chronic kidney disease
peritoneal dialysis
stem cells
low dose
cell therapy
ultrasound guided
mesenchymal stem cells
patient reported